


LATEST ADVANCES IN **RENAL CANCER**

September 7th & 8th, 2023 • Barcelona

Program director: Dr. Cristina Suárez
Senior Researcher of VHIO's Genitourinary,
Central Nervous System (CNS) Tumors,
Sarcoma and Cancer of Unknown Primary Site Group
Oncology Department of Vall d'Hebron University Hospital, Barcelona



On behalf of the VHIO Genitourinary, Central Nervous System (CNS) Tumours, Sarcoma and Cancer of Unknown Primary Site Group, we warmly welcome you to Barcelona for a dynamic and engaging 2-day course focused on the management of patients with renal cell cancer.

By closely connecting clinical and translational researchers at VHIO and the Vall d'Hebron Research Institute (VHIR), we have initiated translational projects.

Over recent years, several advances have been reported in the more effective treatment of GU malignancies. Immunotherapy (IO) is proving increasingly important against bladder and kidney cancers. Concerning the latter, immune-based therapies in combination with others, or paired with antiangiogenics, are considered the new standard treatments for first-line therapy.

The course was designed to review the evidence supporting our current standards of practice, from diagnosis, through surgery and surveillance, and on to the treatment of metastatic disease. Given how fast the field is changing, staying up to date and understanding the nuances of management of these cancers across the care continuum can be a challenge. The faculty selected for this program are experts in the field and will provide practical guidance around common problems encountered in the clinic.

Improving the lives of patients with cancer is our mission at VHIO and we believe that collaboration across disciplines, nationally and internationally, has led to meaningful improvements in the field. We look forward to discussing the rapidly evolving treatment landscape with you.



Dr. Cristina Suárez
Senior Researcher of VHIO's Genitourinary,
Central Nervous System (CNS) Tumors, Sarcoma
and Cancer of Unknown Primary Site Group

LATEST ADVANCES IN RENAL CANCER

THURSDAY, SEPTEMBER 7th, 2023

09:15-09:30

Welcome and course objectives

Cristina Suárez MD PhD / Enrique Trilla MD PhD

09:30-11:00

Chairs: Enrique Trilla MD PhD / Cristina Suárez MD PhD

WHO histological classification. *M^a Eugenia Semidey MD*

Different techniques for localized treatment

- Surgery. *Enrique Trilla MD PhD*
- Ablative techniques. *David Lorente MD PhD*

Murine models and mechanism of resistance to antiangiogenic therapy.

Oriol Casanovas PhD

Q&A

11:00-11:30 **Coffee Break**

11:30-12:45

Chairs: Xavier Maldonado MD PhD / David Lorente MD PhD

Neoadjuvant and adjuvant treatment. *David Marmolejo MD*

First line treatment in RCC. *Cristina Suárez MD PhD*

Role of nephrectomy in advanced disease. *Enrique Trilla MD PhD*

Predictive biomarkers in RCC. *Ana Vivancos PhD*

Q&A

12:45-13:30

Case presentation and discussion. *Cristina Suárez MD PhD*

Case 1: Treatment decision in first line

Case 2: Treatment decision in second line

13:30-14:30 **Lunch**

14:30-16:00

Chairs: Marc Simó MD / David Marmolejo MD

Role of the radiologist in metastatic disease and response evaluation.

Richard Mast MD

The role of liquid biopsy in RCC. *Ana Vivancos PhD*

Treatment of non-clear RCC. *David Marmolejo MD*

Q&A

SCIENTIFIC PROGRAM

FRIDAY, SEPTEMBER 8th, 2023

08:00-09:00

Multidisciplinary Tumor Board. 5th Floor General Hospital

09:30-11:00

Chairs: Xavier Maldonado MD PhD / Enrique Trilla MD PhD

Role of metastasectomy in advanced disease. *David Lorente MD PhD*

Role of SBRT in advanced disease. *Xavier Maldonado MD PhD*

Second-line treatment in RCC and beyond. *Cristina Suárez MD PhD*

Q&A

11:00-11:30 **Coffee Break**

11:30-12:45

Chairs: Cristina Suárez MD PhD / Richard Mast MD

Mechanism of resistance to IO. *María Vieito MD*

Teragnosis in RCC. *Marc Simó MD*

New drugs in RCC. *David Marmolejo MD*

Q&A

12:45-13:15

Wrap-up and conclusions

13:15-14:15 **Lunch**

14:15-15:00

Guided visit to CELLEX

